BERLIN, GERMANY / ACCESSWIRE / April 23, 2024 / Berlin Cures, a pioneering clinical-stage biotechnology company, today announced the successful completion of patient screening for its pan-European Phase II trial of BC 007 (Rovunaptabin), a novel therapeutic candidate for the treatment of Long COVID. The study has no...